Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia
Yoon-Sang Oh, Joong-Seok Kim, Phil Hyu Lee
JMD. 2015;8(2):98-102.   Published online 2015 May 31     DOI: https://doi.org/10.14802/jmd.15041
Citations to this article as recorded by Crossref logo
Current concepts in treating mild cognitive impairment in Parkinson's disease
Jay S. Schneider, Sandhya Kortagere
Neuropharmacology.2022; 203: 108880.     CrossRef
Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis
Łucja Justyna Walczak-Nowicka, Mariola Herbet
International Journal of Molecular Sciences.2021; 22(17): 9290.     CrossRef
Diagnosis and treatment of old-onset Parkinson's disease
久大 立花
Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics.2021; 58(3): 341.     CrossRef
Parkinsonism and dementia
Christos Koros, Leonidas Stefanis, Nikolaos Scarmeas
Journal of the Neurological Sciences.2021; : 120015.     CrossRef
Neuropsychiatrische Störungen bei idiopathischem Parkinson-Syndrom
Mario Paulig
Nervenheilkunde.2021; 40(10): 752.     CrossRef
Cannabis Dopaminergic Effects Induce Hallucinations in a Patient with Parkinson’s Disease
Katie Pizzolato, David Thacker, Nicole Del Toro-Pagán, Abeer Hanna, Jacques Turgeon, Adriana Matos, Nishita Amin, Veronique Michaud
Medicina.2021; 57(10): 1107.     CrossRef
Effectiveness of clozapine, oxcarbazepine and rivastigmine combination in a bipolar disorder patient with initial cerebral atrophy
Paolo Morana, Federico Mucci, Stefano Baroni, Alessandra Della Vecchia, Armando Piccinni, Benedetto Morana, Donatella Marazziti
Clinical Case Reports.2020; 8(2): 254.     CrossRef
Neuropsychiatric Disorders in Parkinson’s Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?
Kathy Dujardin, Véronique Sgambato
Frontiers in Neuroscience.2020;[Epub]     CrossRef
Depression Comorbid With Stroke, Traumatic Brain Injury, Parkinson’s Disease, and Multiple Sclerosis: Diagnosis and Treatment
Susan K. Conroy, Katherine B. Brownlowe, Thomas W. McAllister
FOCUS.2020; 18(2): 150.     CrossRef
Identifying and responding to fatigue and apathy in Parkinson’s disease: a review of current practice
Claudia Lazcano-Ocampo, Yi Min Wan, Daniel J van Wamelen, Lucia Batzu, Iro Boura, Nataliya Titova, Valentina Leta, Mubasher Qamar, Pablo Martinez-Martin, K Ray Chaudhuri
Expert Review of Neurotherapeutics.2020; 20(5): 477.     CrossRef
Diagnosis, treatment and management of apathy in Parkinson’s disease: a scoping review
Bria Mele, Shinia Van, Jayna Holroyd-Leduc, Zahinoor Ismail, Tamara Pringsheim, Zahra Goodarzi
BMJ Open.2020; 10(9): e037632.     CrossRef
Pharmacological treatment of apathy in Lewy body disorders: A systematic review
Jennifer Liu, Christine A. Cooper, Daniel Weintraub, Nabila Dahodwala
Parkinsonism & Related Disorders.2019; 60: 14.     CrossRef
Current treatment of behavioral and cognitive symptoms of Parkinson's disease
Irena Rektorova
Parkinsonism & Related Disorders.2019; 59: 65.     CrossRef
Approach to the management of psychosis in Parkinson’s disease
Abhishek Lenka, Vasanthi Gomathinayagam, Laxman Bahroo
Annals of Movement Disorders.2019; 2(3): 83.     CrossRef
Risk factors for non-motor symptoms in Parkinson's disease
Johan Marinus, Kangdi Zhu, Connie Marras, Dag Aarsland, Jacobus J van Hilten
The Lancet Neurology.2018; 17(6): 559.     CrossRef
The efficacy of pharmacological approaches to therapy of the apathy syndrome in dementia disorders (the review)
A. S. Avedisova, A. B. Guekht, K. V. Zakharova, R. G. Akzhigitov
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2018; 118(4): 126.     CrossRef
Rivastigmine as a Symptomatic Treatment for Apathy in Parkinson’s Dementia Complex: New Aspects for This Riddle
Rita Moretti, Paola Caruso, Matteo Dal Ben
Parkinson's Disease.2017; 2017: 1.     CrossRef
Caregiver Burden in Parkinson Disease: A Critical Review of Recent Literature
Philip E. Mosley, Rebecca Moodie, Nadeeka Dissanayaka
Journal of Geriatric Psychiatry and Neurology.2017; 30(5): 235.     CrossRef
Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson’s Disease: Implication for Treatment
Stephane Thobois, Stephane Prange, Véronique Sgambato-Faure, Léon Tremblay, Emmanuel Broussolle
Current Neurology and Neuroscience Reports.2017;[Epub]     CrossRef
Parkinson's disease psychosis: presentation, diagnosis and management
Ruth B Schneider, Julia Iourinets, Irene H Richard
Neurodegenerative Disease Management.2017; 7(6): 365.     CrossRef
Recent Advance in the Relationship between Excitatory Amino Acid Transporters and Parkinson’s Disease
Yunlong Zhang, Feng Tan, Pingyi Xu, Shaogang Qu
Neural Plasticity.2016; 2016: 1.     CrossRef
Neuropsychiatric Issues in Parkinson’s Disease
Jeffrey W. Cooney, Mark Stacy
Current Neurology and Neuroscience Reports.2016;[Epub]     CrossRef
Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists
Daniel Martinez-Ramirez, Michael S Okun, Michael S Jaffee
Neurodegenerative Disease Management.2016; 6(4): 319.     CrossRef
Pimavanserin for the treatment of Parkinson’s disease psychosis
Ines Chendo, Joaquim J Ferreira
Expert Opinion on Pharmacotherapy.2016; 17(15): 2115.     CrossRef
Apathy in Dementia: Systematic Review of Recent Evidence on Pharmacological Treatments
Fleur Harrison, Liesbeth Aerts, Henry Brodaty
Current Psychiatry Reports.2016;[Epub]     CrossRef
Pharmacotherapies for Parkinson’s disease symptoms related to cholinergic degeneration
Santiago Perez-Lloret, María Cecilia Peralta, Francisco J. Barrantes
Expert Opinion on Pharmacotherapy.2016; 17(18): 2405.     CrossRef